- Home
- TPG vs LEGN Comparison
TPG vs LEGN Comparison
Compare TPG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TPG | LEGN |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TPG | LEGN |
|---|---|---|
| Price | $41.45 | $29.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $61.20 | ★ $61.33 |
| AVG Volume (30 Days) | 2.4M | ★ 2.5M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | $19.79 | $30.52 |
| P/E Ratio | $106.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.95 | $16.24 |
| 52 Week High | $70.38 | $45.30 |
Technical Indicators
Market Signals| Indicator | TPG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 48.75 |
| Support Level | $38.68 | $24.94 |
| Resistance Level | $42.17 | $33.90 |
| Average True Range (ATR) | 1.74 | 1.58 |
| MACD | -0.05 | -0.51 |
| Stochastic Oscillator | 42.65 | 24.32 |
Price Performance
Historical ComparisonAbout TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.